Drug-induced immune thrombocytopenia (DITP) can be triggered by a wide range of
medications. Although many cases of DITP are mild, some are characterized by life …

Drug-induced immune thrombocytopenia (DITP) is a challenging clinical problem that is
under-recognized, difficult to diagnose and associated with severe bleeding complications …

Fifteen monoclonal antibodies (mAbs) are currently registered and approved for the
treatment of a range of different cancers. These mAbs are specific for a limited number of …

Drug‐induced hematological cytopenia is common in kidney transplantation. Various
cytopenia including leucopenia (neutropenia), thrombocytopenia, and anemia can occur in …

Acute infusion reactions are the most common documented adverse reactions reported with
rituximab, with overt cytokine release syndrome, and hematological adverse events being …

The combined information of drug exposure and laboratory test results on an individual
patient level obtained in daily clinical practice can add important information about the safety …

Rituximab use in severe auto-immune diseases has recently increased. Scattered reports of
opportunistic infections were the only reported serious side effects related to rituximab in …

Rituximab is a highly effective agent that is used in the treatment of B-cell lymphoma.
Rituximab-induced acute thrombocytopenia is a rare side effect that has previously been …

Immune thrombocytopenia (ITP) includes different entities characterized by increased
destruction or diminished production of platelets mediated by antibodies against platelet or …

Since its discovery in 1923 and further characterization in 1958, hairy cell leukemia (HCL)
has undergone enormous advances in the understanding of the biology and treatment of the …